Literature DB >> 10449669

A prospective, longitudinal study of pain in head and neck cancer patients.

J M Chaplin1, R P Morton.   

Abstract

BACKGROUND: Little is known about the epidemiology of pain in head and neck cancer, the effects of curative treatment on this pain, and the impact that pain experience may have on patients' quality of life (QL).
METHOD: The prevalence and severity of pain was studied in 93 patients who were first seen with a diagnosis of head and neck cancer, were treated, and remained disease free at two years. QL assessment utilised the life-satisfaction scale and the General Health Questionnaire as specific measures. Pain was assessed by a linear analogue scale anchored by words and numbers.
RESULTS: Forty-eight percent had head and neck pain when first seen, whereas only 25% and 26% had such pain at 12 and 24 months. Approximately 8% of patients rated the pain as "severe" when first seen, whereas 3% had severe pain at 12 months and 4% at 2 years. The prevalence of shoulder and arm pain increased from 14% at diagnosis to 37% at a year and 26% at 24 months, but the percentage of patients with severe pain at any stage postoperatively was only 5% and 2%, respectively. Any pain (pain in either in the head and neck or shoulder and arm or both) at 2 years was strongly predicted by earlier posttreatment pain (at 3 months or at 12 months.) Shoulder and arm pain at 2 years was strongly correlated with surgical treatment of the neck, although no difference in pain experience was noted between those who had radical neck dissections and those who had more conservative procedures. There was no correlation between radiotherapy to the neck and subsequent shoulder and arm pain. Pain had an adverse effect on the general well-being and psychological distress of head and neck cancer patients who were free of disease.
CONCLUSIONS: Pain is common among those presenting with curable head and neck cancer. Pain can be reduced by curative treatment but neck dissection may cause increased shoulder and arm pain. Ongoing pain is predictable and impacts adversely on patients QL. Copyright 1999 John Wiley & Sons, Inc. Head Neck 21: 531-537, 1999.

Entities:  

Mesh:

Year:  1999        PMID: 10449669     DOI: 10.1002/(sici)1097-0347(199909)21:6<531::aid-hed6>3.0.co;2-m

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  34 in total

1.  Cancer patients' and clinicians' opinions on the best time in secondary care to approach patients for recruitment to longitudinal questionnaire-based research.

Authors:  Laura Ashley; Helen Jones; Galina Velikova; Penny Wright
Journal:  Support Care Cancer       Date:  2012-06-22       Impact factor: 3.603

Review 2.  Regional pain syndromes in cancer patients.

Authors:  H A Zekry; E Bruera
Journal:  Curr Rev Pain       Date:  2000

3.  Difficult problems and their solutions in patients with cancer pain of the head and neck areas.

Authors:  T Sist; C Wong
Journal:  Curr Rev Pain       Date:  2000

Review 4.  Head and neck cancer pain: systematic review of prevalence and associated factors.

Authors:  Tatiana V Macfarlane; Tanja Wirth; Sriyani Ranasinghe; Kim W Ah-See; Nick Renny; David Hurman
Journal:  J Oral Maxillofac Res       Date:  2012-04-01

Review 5.  The development of an ICF-based clinical guideline and screening tool for the standardized assessment and evaluation of functioning after head and neck cancer treatment.

Authors:  Ulrich Kisser; Christine Adderson-Kisser; Michaela Coenen; Marita Stier-Jarmer; Sven Becker; Carla Sabariego; Ulrich Harréus
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-09-30       Impact factor: 2.503

6.  Identifying pain-related concerns in routine follow-up clinics following oral and oropharyngeal cancer.

Authors:  Simon N Rogers; Alexander J Cleator; Derek Lowe; Naseem Ghazali
Journal:  World J Clin Oncol       Date:  2012-08-10

7.  Incidence of severe pain in newly diagnosed ambulatory patients with stage IV cancer.

Authors:  Thomas Isaac; Sherri O Stuver; Roger B Davis; Susan Block; Jane C Weeks; Donna L Berry; Saul N Weingart
Journal:  Pain Res Manag       Date:  2012 Sep-Oct       Impact factor: 3.037

8.  Caregiver-reported neuropsychiatric symptoms in patients undergoing treatment for head and neck cancer: a pilot study.

Authors:  Stewart M Bond; Deborah K Hawkins; Barbara A Murphy
Journal:  Cancer Nurs       Date:  2014 May-Jun       Impact factor: 2.592

9.  Short-term health-related quality of life and symptom control with docetaxel, cisplatin, 5-fluorouracil and cisplatin (TPF), 5-fluorouracil (PF) for induction in unresectable locoregionally advanced head and neck cancer patients (EORTC 24971/TAX 323).

Authors:  C M L van Herpen; M E Mauer; R Mesia; M Degardin; S Jelic; C Coens; J Betka; J Bernier; E Remenar; J S Stewart; J H Preiss; D van den Weyngaert; A Bottomley; J B Vermorken
Journal:  Br J Cancer       Date:  2010-09-14       Impact factor: 7.640

10.  Endothelin-A receptor antagonism attenuates carcinoma-induced pain through opioids in mice.

Authors:  Phuong N Quang; Brian L Schmidt
Journal:  J Pain       Date:  2010-01-13       Impact factor: 5.820

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.